Head & Neck Cancer and Glioblastoma

  1. EGFR Expression Test (EGFR IHC)
    1. Indication: nasopharyngeal cancer
    2. Function: predict the effectivity of anti epidermal growth factor receptor/ EGFR (nimotuzumab)
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells
    4. Analyte: protein
    5. Method: immunohistochemistry
    6. Interpretation: expression of EGFR (+3) is eligible for anti EGFR therapy
    7. TAT: 7 working days

  2. MGMT Methylation Detection Test
    1. Indication: glioblastoma
    2. Function: predict the effectivity of anti epidermal growth factor receptor/ EGFR (nimotuzumab) or temozolomide
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or stained/ unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells
    4. Analyte: DNA
    5. Method: real time PCR
    6. Interpretation: methylation is eligible for nimotuzumab but not eligible for temozolomide
    7. TAT: 7 working days
Advertisements